Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen files PLA for Avonex beta interferon multiple sclerosis treatment.

Executive Summary

BIOGEN AVONEX FILING IS FIRST PROPRIETARY PLA FILING for the Cambridge, Mass.-based company, Biogen noted when it reported that it filed a PLA May 22 for its recombinant interferon beta for treatment of multiple sclerosis. "This is the first time Biogen has filed in the U.S. for regulatory approval of a proprietary Biogen drug," Biogen said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026259

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel